Somewhat Favorable News Coverage Somewhat Unlikely to Impact AnaptysBio (ANAB) Stock Price

Media coverage about AnaptysBio (NASDAQ:ANAB) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AnaptysBio earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.5955392594543 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Several brokerages recently commented on ANAB. Robert W. Baird reiterated a “buy” rating and issued a $144.00 price objective (up previously from $81.00) on shares of AnaptysBio in a research note on Friday, January 19th. Zacks Investment Research cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Credit Suisse Group set a $135.00 price objective on shares of AnaptysBio and gave the company an “outperform” rating in a research note on Tuesday, January 23rd. SunTrust Banks raised their price objective on shares of AnaptysBio from $115.00 to $162.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Royal Bank of Canada raised their price objective on shares of AnaptysBio to $108.00 and gave the company an “outperform” rating in a research note on Monday, December 18th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. AnaptysBio has a consensus rating of “Buy” and an average target price of $131.44.

Shares of NASDAQ ANAB opened at $88.20 on Friday. The company has a quick ratio of 17.93, a current ratio of 17.93 and a debt-to-equity ratio of 0.02. AnaptysBio has a 52 week low of $18.15 and a 52 week high of $134.00. The stock has a market capitalization of $2,169.32, a P/E ratio of -58.03 and a beta of 3.26.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 5th. The biotechnology company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.12. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $0.89 million. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. research analysts anticipate that AnaptysBio will post -2.3 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with's FREE daily email newsletter.

Leave a Reply